Tekmira announces research deal with Pfizer
Canadian biopharmaceutical company Tekmira Pharmaceuticals Corp. said Tuesday it has entered into a new research collaboration with Pfizer Inc., the world's largest drugmaker.
Tekmira, which is based in Vancouver, British Columbia, said it focuses on developing drugs that can treat an array of conditions by silencing disease-causing genes. It will work with Pfizer to evaluate its stable nucleic acid-lipid particle technology that will be used to deliver therapeutic molecules provided by Pfizer.
Terms of the deal where not disclosed.
Pfizer shares climbed 6 cents to $17.32 in late-morning trading Tuesday.